Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

435
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

276
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
276
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

4.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
4.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating hydrodynamic and predictive ecological modelling to forecast the effects of climate change on urban stream macroinvertebrates.

Journal of environmental management·2026
Same author

Pilot Alkaline Extraction of <i>Eucalyptus globulus</i> Bark: A Natural Sustainable Solution for Wood Preservation.

Antioxidants (Basel, Switzerland)·2026
Same author

Polyphenols as next-generation prebiotics targeting intestinal mucosal tolerance.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Optimization of Emerging Extraction Techniques for Phenolic Compounds from <i>Pinus radiata</i> Bark: Antioxidant, Thermal Stability and Antibacterial Properties.

Antioxidants (Basel, Switzerland)·2026
Same author

Sexual violence against children and adolescents: analysis in peripheral contexts in the metropolis of São Paulo, Brazil.

Archives of public health = Archives belges de sante publique·2026
Same author

Oleacein prevents metabolic dysfunction-associated hepatic steatosis and dyslipidaemia in ApoE-KO mice.

Food & function·2026

Related Experiment Video

Updated: Sep 18, 2025

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
12:32

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds

Published on: January 23, 2018

12.5K

miRNA-642a-3p protects β cells from glucolipotoxicity.

Sandra Sofia Pinhanços1,2,3,4, João Teixeira de Oliveira5,6, C Henrique Alves7,8,9,3

  • 1CNC - Center for Neuroscience and Cell Biology, University of Coimbra, 3060-197 Coimbra, Portugal.

Molecular Therapy. Nucleic Acids
|June 23, 2025
PubMed
Summary

Researchers identified miR-642a-3p, a microRNA that protects pancreatic beta cells from glucolipotoxicity (GLT)-induced cell death. This finding offers a potential new tool for managing diabetes and obesity.

Keywords:
MT: Non-coding RNAsbariatric surgerydiabetesextracellular vesiclesglucolipotoxicitymicroRNAsobesityβ cells

More Related Videos

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.8K
Studying TGF-&#946; Signaling and TGF-&#946;-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.3K

Related Experiment Videos

Last Updated: Sep 18, 2025

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
12:32

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds

Published on: January 23, 2018

12.5K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.8K
Studying TGF-&#946; Signaling and TGF-&#946;-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.3K

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Genetics

Background:

  • Type 2 diabetes mellitus (T2DM) incidence correlates with obesity.
  • Glucolipotoxicity (GLT), high glucose and fatty acids, impairs beta cell function and survival.
  • Identifying protective mechanisms against GLT is crucial for T2DM management.

Purpose of the Study:

  • To screen for microRNAs (miRNAs) that protect pancreatic beta cells from GLT-induced cell death (GICD).
  • To investigate the role of a specific miRNA, miR-642a-3p, in beta cell protection and function.

Main Methods:

  • Screened a library of 2,080 human miRNA mimics in beta cells exposed to GLT.
  • Utilized RNA-sequencing to analyze gene expression changes induced by miR-642a-3p.
  • Assessed insulin secretion and miRNA expression in human islets and extracellular vesicles from obese and T2DM patients.

Main Results:

  • Identified 45 miRNAs protecting beta cells from GICD; selected miR-642a-3p for further study.
  • miR-642a-3p restored beta cell identity genes, modulated cell survival and lipid metabolism pathways.
  • miR-642a-3p protected beta cells from GLT-induced insulin secretion dysfunction.
  • miR-642a-3p was downregulated in T2DM patient islets; its protective role was altered in obese patients.

Conclusions:

  • miR-642a-3p shows potential as a biomarker for T2DM and obesity.
  • miR-642a-3p acts as a facilitator of beta cell survival and function.
  • This miRNA represents a novel theranostic target for diabetes and obesity management.